Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?
Files
Publication date
2018-02
Authors
Ong, David S. Y.
van Werkhoven, Henri
Cremer, Olaf L.
Thwaites, Guy E
Bonten, Marc J M
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Short-term adjunctive treatment with aminoglycosides in critically ill patients is advocated in guidelines for the empirical treatment of sepsis, despite lack of evidence from randomized trials. A large observational study recently reported more nephrotoxicity and a trend to worse patient outcome in critically ill patients receiving aminoglycosides added to beta-lactam antibiotics. Here, we discuss if a randomized controlled trial to obtain a more definite answer is justified and how it could be performed.
Keywords
Aminoglycoside, Combination therapy, Gentamicin, Mortality, Nephrotoxicity, Sepsis, Taverne, Microbiology (medical), Infectious Diseases, Journal Article
Citation
Ong, D S Y, van Werkhoven, C H, Cremer, O L, Thwaites, G E & Bonten, M J M 2018, 'Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?', Clinical Microbiology and Infection, vol. 24, no. 2, pp. 95-96. https://doi.org/10.1016/j.cmi.2017.09.020